Literature DB >> 17869378

Anti-cancer PEG-enzymes: 30 years old, but still a current approach.

Gianfranco Pasut1, Mauro Sergi, Francesco M Veronese.   

Abstract

PEGylation (i.e. the covalent link of PEG strands) is a well known technique used to improve pharmaceutical properties of bioactive proteins and peptides. Even in cancer therapy some proteins, in particular enzymes, can find many applications, because of their antiproliferative action or ability to reduce side effects of chemotherapies, but to do so they need to be properly formulated. Unfortunately, formulation alone can not fulfil all the requirements to yield a safe and successful protein preparation for therapeutic applications. In particular, for many proteins fast clearance from the body and potential immunogenicity are severe limitations, which can not be easily overcome without taking into consideration a purposely designed drug delivery system. Among the approaches in the field of drug delivery, PEGylation has so far been the best choice for protein delivery. Here, we describe some examples of PEGylated enzymes useful in antitumoral therapies and the most recent advances in this field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869378     DOI: 10.1016/j.addr.2007.04.018

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  23 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

2.  Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity.

Authors:  Thomas J Rutkoski; John A Kink; Laura E Strong; Ronald T Raines
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

3.  Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.

Authors:  Mehdi Imani; Serveh Shahmohamadnejad
Journal:  3 Biotech       Date:  2017-06-30       Impact factor: 2.406

4.  In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation.

Authors:  Weiping Gao; Wenge Liu; Trine Christensen; Michael R Zalutsky; Ashutosh Chilkoti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-01       Impact factor: 11.205

5.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

6.  Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.

Authors:  Kara Lea Vine; Sergei Lobov; Vineesh Indira Chandran; Nathanial Lachlan Ewart Harris; Marie Ranson
Journal:  Pharm Res       Date:  2014-09-18       Impact factor: 4.200

Review 7.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

8.  Mechanistic examination of protein release from polymer nanofibers.

Authors:  M Gandhi; R Srikar; A L Yarin; C M Megaridis; R A Gemeinhart
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

9.  Enzymatic activity and thermal stability of PEG-alpha-chymotrypsin conjugates.

Authors:  José A Rodríguez-Martínez; Izarys Rivera-Rivera; Ricardo J Solá; Kai Griebenow
Journal:  Biotechnol Lett       Date:  2009-02-18       Impact factor: 2.461

10.  Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Authors:  Patrick A Ott; Richard D Carvajal; Neeta Pandit-Taskar; Achim A Jungbluth; Eric W Hoffman; Bor-Wen Wu; John S Bomalaski; Ralph Venhaus; Linda Pan; Lloyd J Old; Anna C Pavlick; Jedd D Wolchok
Journal:  Invest New Drugs       Date:  2012-08-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.